SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

ARISTADA

ALKS·Alkermes plc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since 2015 (ARISTADA) and 2018 (ARISTADA INITIO).
Why 4/10
ARISTADA is already FDA-approved and commercially marketed with no pending PDUFA, pivotal readout, or regulatory decision for the drug itself. The next hard catalysts for Alkermes are orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027), not ARISTADA. Per the impact rubric, an approved drug with no pending binary catalyst scores 3-5.
Actionable Insight NEUTRAL

ARISTADA is a mature commercial asset with no upcoming binary catalyst; the stock's next major value inflection points are the orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027). Watch ARISTADA's quarterly sales trajectory for competitive erosion signals from newer LAIs like UZEDY and Invega Hafyera, but the drug's patent protection through 2039 limits near-term generic risk.

Price Chart

Loading chart...

Executive Summary

ARISTADA (aripiprazole lauroxil) is Alkermes' FDA-approved long-acting injectable antipsychotic for schizophrenia, first approved in 2015 with an initiation product (ARISTADA INITIO) approved in 2018. It offers flexible dosing every month, six weeks, or two months. The drug generated approximately $370M in 2025 net sales (about 31% of Alkermes' proprietary revenue) and is guided at $365M-$385M for full-year 2026. Patent protection extends to roughly 2039. ARISTADA is a mature commercial asset in a competitive LAI market against J&J's Invega franchise, Otsuka's Abilify Maintena, and newer entrants. The ALPINE Phase 3b study showed comparable efficacy to Invega Sustenna. With no pending regulatory catalysts for ARISTADA itself, the stock's next major catalysts are Alkermes' orexin pipeline readouts expected in 2027.

How It Works

ARISTADA is a long-acting injectable version of aripiprazole (Abilify), an atypical antipsychotic. It works by modulating dopamine and serotonin receptors in the brain to control schizophrenia symptoms. Instead of taking a daily pill, patients receive an intramuscular injection by a healthcare professional every month, every six weeks, or every two months, which releases the medication slowly over time. This helps patients stay on treatment and avoid relapses from missed daily doses.

Trial Status

ARISTADA is FDA-approved and commercially marketed. The Phase 3b ALPINE study (completed) compared ARISTADA head-to-head against Invega Sustenna and showed comparable efficacy. Alkermes continues to generate real-world evidence and present data at medical conferences.

The Two-Sided Case

▲ Bull Case5
ARISTADA is a well-established, FDA-approved long-acting injectable for schizophrenia with flexible dosing (monthly, 6-week, and 2-month options), offering convenience that supports adherence vs daily oral antipsychotics.
Patent protection extends to approximately April 2039, providing a long runway of exclusivity with no near-term generic threat.
The ALPINE Phase 3b study demonstrated ARISTADA's efficacy was comparable to Invega Sustenna, providing physicians with head-to-head data to support prescribing decisions.
Alkermes guided full-year 2026 ARISTADA net sales of $365M-$385M, and Q3 2026 sales of $103.9M were tracking within that range, showing the franchise remains stable at roughly $370M+ annually.
Institutional ownership is strong, with BlackRock holding ~$1.53B, Baker Bros. ~$525M, and Vanguard ~$497M in ALKS as of Q2 2026, and several funds added or doubled positions that quarter.
▼ Bear Case4
ARISTADA net sales declined slightly year-over-year in Q2 2026 ($96.7M vs $101.3M), signaling competitive pressure in the LAI antipsychotic market from J&J's Invega Sustenna/Trinza/Hafyera, Otsuka's Abilify Maintena, and newer entrants like UZEDY.
Patent expiry is distant (2039) but the drug faces a mature, increasingly crowded market where differentiation is difficult; the ALPINE trial showed comparable (not superior) efficacy to Invega Sustenna.
Alkermes' Q3 2026 GAAP net income fell to $16.3M from $87.1M a year earlier due to higher R&D and SG&A costs from the Avadel acquisition and pipeline investment, pressuring near-term profitability.
The stock's 52-week high of $55.67 is well above the current $45.89, and the stock has underperformed from that level.

Upcoming Catalysts

  • No upcoming regulatory catalysts for ARISTADA specifically; it is a marketed product.
  • Alkermes' broader catalysts include orexin portfolio readouts: Phase 3 alixorexton narcolepsy data expected mid-2027, and Phase 2 data for ALKS 7290 in ADHD.
  • Quarterly ARISTADA net sales reports will continue to track competitive dynamics in the LAI antipsychotic market.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alkermes plc. 8-K ALKS ·Originating report

Sources · 10

Hover a chip for the title
1 alkermesmedicalaffairs.com2 accessdata.fda.gov3 drugs.com4 businesswire.com5 fool.com6 investor.alkermes.com7 investing.com8 cliffbio.com9 atlantisdatasolutions.com10 stockanalysis.com